Pfizer  logo
Pfizer PFE
$ 25.23 -0.26%

Quarterly report 2025-Q3
added 11-04-2025

report update icon

Pfizer Cash Flow 2011-2025 | PFE

Annual Cash Flow Pfizer

2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Operating Cash Flow

12.7 B 8.7 B 29.3 B 32.6 B 14.4 B 12.6 B 15.8 B 16.8 B 16.2 B 14.7 B 17.1 B 17.7 B 16.7 B 20.2 B

Depreciation & Amortization

7.01 B 6.29 B 5.06 B 5.19 B 4.68 B 5.76 B 6.38 B 6.27 B 5.76 B 5.16 B 5.54 B 6.31 B 7.39 B 8.7 B

Accounts Payables

5.63 B 6.71 B 6.81 B 5.58 B 4.31 B 4.22 B 4.67 B 4.66 B 4.54 B 3.62 B 3.44 B 3.23 B 4.26 B 3.84 B

Accounts Receivables

11.5 B 11.6 B 11 B 11.5 B 7.93 B 8.72 B 8.02 B 8.22 B 8.22 B 8.18 B 8.67 B 9.36 B 12.4 B 13.6 B

Total Inventories

10.9 B 10.2 B 8.98 B 9.06 B 8.05 B 8.28 B 7.51 B 7.58 B 6.78 B 7.51 B 5.66 B 6.17 B 7.06 B 7.77 B

All numbers in USD currency

Quarterly Cash Flow Pfizer

2025-Q3 2025-Q2 2025-Q1 2024-Q3 2024-Q2 2024-Q1 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Operating Cash Flow

- - 2.34 B - - 1.09 B - - 1.21 B - 20.7 B 14.7 B 6.54 B - 26.7 B 15.8 B 4.54 B - 8.78 B 6.69 B 3.13 B - 8.82 B 4.31 B 1.7 B - 11.1 B 5.83 B 1.98 B - 9.71 B 4.82 B 1.58 B - 10.2 B 5.41 B 1.81 B - 9.79 B 4.77 B 680 M - 11.5 B 7.02 B 2.94 B - 12 B 6.06 B 2.3 B - 11.8 B 6.8 B 2.77 B - 15 B 10.5 B 4.64 B

Depreciation & Amortization

1.66 B 1.62 B 1.62 B 1.76 B 1.73 B 1.74 B - - 1.49 B - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 1.1 B 1.2 B 1.77 B - 5.55 B 3.89 B 2.22 B - 6.57 B 4.35 B 2.1 B

Accounts Payables

5.02 B 5.17 B 5.24 B 5.31 B 5.11 B 5.59 B 5.34 B 6.08 B 6.12 B 6.81 B 6.27 B 6.21 B 5.51 B 5.58 B 4.7 B 4.33 B 4.06 B 4.28 B 4.31 B 4.31 B 4.31 B 3.89 B 4.22 B 4.22 B 4.22 B 4.67 B 4.67 B 4.67 B 4.67 B 4.66 B 4.66 B 4.66 B 4.66 B 4.54 B 4.54 B 4.54 B 4.54 B 3.62 B 3.62 B 3.62 B 3.62 B 3.21 B 3.21 B 3.21 B 3.21 B 3.23 B 3.23 B 3.23 B 3.23 B 2.92 B 2.92 B 2.92 B 4.26 B 3.68 B 3.68 B 3.68 B 3.84 B

Accounts Receivables

14.3 B 12.1 B 11.8 B 14.5 B 11.4 B 11 B 11.1 B 10.2 B 12.3 B 11 B 16.1 B 15.2 B 13.2 B 11.5 B 11.9 B 10.6 B 9.86 B 7.91 B 7.93 B 7.93 B 7.93 B 6.77 B 8.72 B 8.72 B 8.72 B 8.02 B 8.02 B 8.02 B 8.02 B 8.22 B 8.22 B 8.22 B 8.22 B 8.22 B 8.22 B 8.22 B 8.22 B 8.18 B 8.18 B 8.18 B 8.18 B 8.4 B 8.4 B 8.4 B 8.67 B 9.36 B 9.36 B 9.36 B 9.36 B 10.7 B 11.5 B 11.5 B 12.4 B 13.1 B 13.1 B 13.1 B 13.6 B

Total Inventories

11.5 B 11.7 B 10.9 B 11.7 B 11.4 B 10.9 B 10.2 B 10.3 B 9.54 B 8.98 B 9.51 B 10.5 B 9.98 B 9.06 B 8.64 B 8.95 B 8.49 B 8.02 B 8.05 B 8.05 B 8.05 B 7.07 B 8.28 B 8.28 B 8.28 B 7.51 B 7.51 B 7.51 B 7.51 B 7.58 B 7.58 B 7.58 B 7.58 B 6.78 B 6.78 B 6.78 B 6.78 B 7.51 B 7.51 B 7.51 B 7.51 B 5.66 B 5.66 B 5.66 B 5.66 B 6.17 B 6.17 B 6.17 B 6.17 B 6.08 B 6.08 B 6.08 B 7.06 B 6.61 B 6.61 B 6.61 B 6.97 B

All numbers in USD currency

Cash Flow Statement is one of the three key financial reports of the company Pfizer , reflecting the actual cash inflows and outflows over a certain period. Unlike the income statement, which shows revenues and expenses on an accrual basis, the cash flow statement focuses on real cash flows — how much cash actually came into the company and how much was spent.

Main Sections of the Cash Flow Statement
  • Operating Activities
    This section reflects cash flows related to the company’s core operations: receipts from sales of goods and services, payments to suppliers, employee salaries, taxes, and other operating expenses. Positive cash flow from operating activities indicates the viability of the business and its ability to generate cash.
  • Investing Activities
    Shows cash movements related to the purchase and sale of long-term assets such as real estate, equipment, and investments in other companies. Negative cash flow here often indicates investments in growth, which can be a positive sign.
  • Financing Activities
    Reflects the inflow and outflow of cash related to raising and repaying capital: issuing shares, loans, dividend payments, and loan repayments. This section shows how the company finances its activities and distributes profits.

The cash flow statement is important for investors because it allows them to assess the company’s real liquidity, showing whether it has enough cash to cover current obligations and investments — this is critical for financial stability. Additionally, it helps analyze the quality of earnings, since profits reported in the income statement can be "paper" profits and may not reflect actual cash inflows; the cash flow statement reveals this difference. The presence of free cash is also crucial for evaluating the company’s ability to finance growth and pay dividends, which is important for investors. Attention should also be paid to prolonged negative cash flows from operating activities, as this may serve as a warning sign of potential problems with the core business.

Cash flow statements of other stocks in the Biotechnology sector

Issuer Price % 24h Market Cap Country
AC Immune SA AC Immune SA
ACIU
$ 2.8 2.19 % $ 229 M schweizSchweiz
ADiTx Therapeutics ADiTx Therapeutics
ADTX
$ 2.49 -11.39 % $ 32.8 K usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
- 5.93 % $ 314 M canadaCanada
Abeona Therapeutics Abeona Therapeutics
ABEO
$ 4.59 -4.08 % $ 98.1 M usaUSA
ARCA biopharma ARCA biopharma
ABIO
- 1052.0 % $ 415 M usaUSA
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
- - $ 26.5 M usaUSA
Akouos Akouos
AKUS
- 0.23 % $ 488 M usaUSA
Amneal Pharmaceuticals Amneal Pharmaceuticals
AMRX
$ 12.12 -1.58 % $ 3.74 B usaUSA
Axcella Health Axcella Health
AXLA
- -16.42 % $ 249 M usaUSA
Acer Therapeutics Acer Therapeutics
ACER
- 2.71 % $ 14 M usaUSA
Armata Pharmaceuticals Armata Pharmaceuticals
ARMP
$ 5.37 -20.68 % $ 194 M usaUSA
Atreca Atreca
BCEL
- -11.76 % $ 5.79 M usaUSA
Brainstorm Cell Therapeutics Brainstorm Cell Therapeutics
BCLI
- -2.5 % $ 5.88 M usaUSA
argenx SE argenx SE
ARGX
$ 919.62 2.76 % $ 25 B niderlandNiderland
Ascendis Pharma A/S Ascendis Pharma A/S
ASND
$ 203.0 -3.72 % $ 5 B danmarkDanmark
Achieve Life Sciences Achieve Life Sciences
ACHV
$ 4.64 -0.32 % $ 92 M usaUSA
BioDelivery Sciences International BioDelivery Sciences International
BDSI
- -4.8 % $ 255 M usaUSA
BeiGene, Ltd. BeiGene, Ltd.
BGNE
- 0.49 % $ 251 B cayman-islandsCayman-islands
Acorda Therapeutics Acorda Therapeutics
ACOR
- -24.86 % $ 820 K usaUSA
Alterity Therapeutics Limited Alterity Therapeutics Limited
ATHE
$ 3.36 2.73 % $ 8.08 B australiaAustralia
Acasti Pharma Acasti Pharma
ACST
- 4.01 % $ 150 M canadaCanada
Bellerophon Therapeutics Bellerophon Therapeutics
BLPH
- -74.18 % $ 955 K usaUSA
BioLineRx Ltd. BioLineRx Ltd.
BLRX
$ 3.29 -1.5 % $ 908 M israelIsrael
BioMarin Pharmaceutical BioMarin Pharmaceutical
BMRN
$ 54.27 -1.38 % $ 10.3 B usaUSA
Adaptimmune Therapeutics plc Adaptimmune Therapeutics plc
ADAP
- -15.15 % $ 60.3 M britainBritain
Baudax Bio Baudax Bio
BXRX
- 0.59 % $ 63 K usaUSA
AbbVie AbbVie
ABBV
$ 224.99 -0.01 % $ 398 B usaUSA
Cara Therapeutics Cara Therapeutics
CARA
- -3.03 % $ 260 M usaUSA
CymaBay Therapeutics CymaBay Therapeutics
CBAY
- - $ 3.45 B usaUSA
ChemoCentryx ChemoCentryx
CCXI
- - $ 3.74 B usaUSA
BioNTech SE BioNTech SE
BNTX
$ 96.22 -1.21 % $ 27.2 B germanyGermany
Codiak BioSciences Codiak BioSciences
CDAK
- -55.98 % $ 2.15 M usaUSA
Adaptive Biotechnologies Corporation Adaptive Biotechnologies Corporation
ADPT
$ 18.75 -0.48 % $ 2.76 B usaUSA
Avid Bioservices Avid Bioservices
CDMO
- - $ 789 M usaUSA
BioXcel Therapeutics BioXcel Therapeutics
BTAI
$ 1.92 -7.01 % $ 4.87 M usaUSA
Biogen Biogen
BIIB
$ 179.76 1.11 % $ 26.2 B usaUSA
Cerevel Therapeutics Holdings Cerevel Therapeutics Holdings
CERE
- - $ 7.29 B usaUSA
ContraFect Corporation ContraFect Corporation
CFRX
- -5.16 % $ 5.39 M usaUSA
Beam Therapeutics Beam Therapeutics
BEAM
$ 23.52 -2.22 % $ 1.94 B usaUSA
AbCellera Biologics AbCellera Biologics
ABCL
$ 3.45 -0.72 % $ 1.02 B canadaCanada
Cabaletta Bio Cabaletta Bio
CABA
$ 2.37 -2.67 % $ 2.77 M usaUSA
Clearside Biomedical Clearside Biomedical
CLSD
- - $ 25.3 M usaUSA
Celsion Corporation Celsion Corporation
CLSN
- -6.63 % $ 13.9 M usaUSA
Clovis Oncology Clovis Oncology
CLVS
- -7.23 % $ 13 M usaUSA
Advaxis Advaxis
ADXS
- -9.65 % $ 45.9 M usaUSA
Checkmate Pharmaceuticals Checkmate Pharmaceuticals
CMPI
- - $ 231 M usaUSA
Chimerix Chimerix
CMRX
- - $ 756 M usaUSA
Concert Pharmaceuticals Concert Pharmaceuticals
CNCE
- - $ 401 M usaUSA